Clinical Trial Search

Primary: Percent Change From Baseline in Body Weight in LY3502970 and Placebo — -8.6; -11.2; -12.3; -12.6 Percent change — p=<0.001

Primary: Number of Participants With Diagnostic Findings That Lead to a Change in Acute Treatment or Treatment for Secondary Prevention — 64; 390; 86; 368 Participants

Primary: Principal Investigator's Assessment of Improvement at 12 Weeks Post-final Treatment (Physician's Global Assessment of Improvement=GAIS) — 1.04 score on a scale

Primary: Tumor Necrosis Factor-alpha — 1.05; 0.93; 1.04; 1.18 pg/mL

Primary: Mean Percent Change From Baseline in Body Weight — -1.55; -7.18; -12.00; -13.80 percent change — p=<0.001

Primary: Overall Arrest Rates — 81.3; 61.5; 78.1; 95.8 percentage of lesions arrested

Primary: 11C-ER176 Total Distribution Volume — 6.27; 9.32 mL/cm^3

Primary: Mean and Standard Deviation of Differences Between Masimo NIBP Device and Manual Sphygmomanometer Measurements. — -1.23; -2.67 mmHg

Primary: Child Body Mass Index Z-score (BMIz) at Baseline and Month 8 — 1.78; 1.92; 1.78; 1.96 Z-score

Primary: Number of Participants Who Experienced a Wound Complication (A Measure of Dressing Safety) — 4; 0; 0 Participants

Primary: Number of Participants With Any Adverse Events — 417 Participants

Primary: Combined Circumference Reduction in Inches of the Waist, Hips, and Bilateral Thighs — -3.91 inches

Primary: Percentage of Participants With Clinical Response at Week 16 — 49.1; 37.4 Percentage of participants — p=0.089

Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies Against Each of the Four Influenza Vaccine Strains as Measured by HI Assay — 178; 179; 111…

Primary: Change in Brain Temperature — -0.23; -0.03 degrees Celsius — p=0.02